

About SOPHiA GENETICS™

SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by a broad network of hospital, laboratory, and biopharma institutions globally.

SOPHiA GENETICS was founded in 2011 as a startup at École Polytechnique Fédérale de Lausanne (EPFL) in Lausanne, Switzerland.

Our Mission

Our mission is to provide equal access to knowledge and capabilities by democratizing data-driven medicine. We aim to be the global platform that allows healthcare professionals to leverage their expertise and work together around the world – unlocking the promise of data-driven medicine at scale.

Founders

Jurgi Camblong _____ Chief Executive Officer

Pierre Hutter

Lars Steinmetz

Office Locations

Rolle (Global Headquarters) Switzerland

Boston _____ Massachusetts USA

Bidart _____ France

Key People

Peter Casasanto _____ Chief BioPharma Officer

Ken Freedman _____ Chief Revenue Officer

Philippe Menu _____ Chief Medical Officer

Ross Muken _____ Chief Financial Officer & Chief Operating Officer

Kevin Puylaert _____ Managing Director, EMEA

Manuela Valente _____ Chief People Officer

Daan Van Well _____ Chief Legal Officer, General Counsel

Abhimanyu Verma _____ Chief Technology Officer

Zhenyu Xu _____ Chief Scientific Officer

Employees

- 450 in 27 countries ⁽¹⁾
- 30% of employees hold a PhD
- 48% work in R&D

¹ Data as of Jul 31, 2023

Finance

IPO Valuation: \$1.1B


Ticker Symbol: **SOPH** on Nasdaq

About the SOPHiA DDM™ Platform

SOPHiA GENETICS is the creator of SOPHiA DDM™, a cloud-based platform capable of analyzing data and generating insights from complex multimodal data sets and different modalities. The SOPHiA DDM™ platform enables healthcare institutions to get quick, robust insights from their data. We apply our technology to areas such as cancer and inherited disorders, where combining genomic and phenotypic information is vital to support research and drug development efforts.



SOPHiA DDM™ in lab environment



SOPHiA DDM™ in medical settings




Benefits for all

SOPHiA GENETICS' data-sharing methodology also helps researchers and healthcare professionals work together as a community by sharing and leveraging patterns identified via artificial intelligence and machine learning. Our universal platform is designed to improve as we analyze more data over time.

The SOPHiA DDM™ platform is one of the largest technology-agnostic networks of connected healthcare institutions worldwide and is currently **used by more than 750 hospital, laboratory, and biopharma institutions globally².**

² as of December 31, 2021



Awards and Recognition

- **Swiss Biotech Association** _____ 2023 Swiss Biotech Success Stories Award
- **Fast Company** _____ World's Most Innovative Companies for 2023
- **The Healthcare Technology Report** _____ 2022 The Top 100 Healthcare Technology Companies
- **Built In Boston** _____ 2022 Best Places to Work - Boston
- **BioAlps Association** _____ 2021 Industry Award
- **Microsoft** _____ 2021 Partner of the Year finalist
- **Healthcare Medtech Asia Awards** _____ 2021 Hospital Partnership of the Year Australia & 2021 Oncology Product Innovation of the Year, Australia
- **Tech Tour Growth 50** _____ 2019 Growth Award
- **Convergence in Oncology Summit** _____ 2018 Salus Partner Excellence in HealthTech Award
- **MIT Tech Review** _____ Ranked #30 in 50 Smartest Companies, 2017

Media Inquiries: media@sophiagenetics.com